Lisa Stehno-Bittel, PhD
President & Founder
In 2012, Lisa licensed her laboratory patents from the University of Kansas and co-founded the company Likarda. The patents had applications in drug screening for efficacy and toxicity, as well as the ability to transform cell-based therapeutics. The first focus was to build the screening side of the business by providing consultation and direct research services. Within 17 months of launching, Likarda was revenue positive and in 2012 was chosen, during Global Entrepreneurship Week, as one of the top 50 Most Promising Start-Ups in the World. As the service division of Likarda grows, she and her team are developing a cell-based solution for dogs with diabetes, which will be an injectable islet transplant that will remove the need for daily insulin injections for diabetic dogs.
Lisa began her career in health care as a physical therapist. With more than 25 years of research experience in the fields of cell biology and diabetes, she has over 65 publications in scientific journals and received more than $9 million in grant funding for her research. Lisa currently holds a part-time faculty position at the University of Kansas Medical Center, where she served as the chair of a department prior to 2015. She holds a bachelor’s degree from the University of Kansas, a PhD from the University of Missouri, and completed a pharmacology fellowship at the Mayo School of Medicine. Global Medical Discovery identified Lisa’s work in immunosuppression of autoimmune-induced type 1 diabetes as a Key Scientific Discovery.
Lisa has received numerous awards, including the Outstanding Faculty Research Award from the University of Kansas Medical Center and the Jim Baxendale Commercialization Award. Ingram’s Magazine named her one of “50 Kansans You Should Know” and Lisa was awarded the Women in Medicine and Science Sirridge award for female role models. Faculty Row designated Lisa a Super Professor.